Insider Buying: Fractyl Health (NASDAQ:GUTS) Director Acquires $25,550.00 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director Ian Sheffield bought 35,000 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was acquired at an average cost of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the purchase, the director directly owned 35,000 shares in the company, valued at approximately $25,550. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Fractyl Health Trading Up 17.4%

GUTS opened at $0.85 on Friday. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The company’s 50 day simple moving average is $0.69 and its two-hundred day simple moving average is $1.07. Fractyl Health, Inc. has a 1-year low of $0.38 and a 1-year high of $2.45. The firm has a market capitalization of $134.85 million, a price-to-earnings ratio of -0.66 and a beta of 2.34.

Fractyl Health (NASDAQ:GUTS) last released its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. Analysts expect that Fractyl Health, Inc. will post -0.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on GUTS. Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research report on Thursday, March 26th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research report on Thursday, June 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.40.

Institutional Trading of Fractyl Health

Several institutional investors have recently made changes to their positions in the company. Pale Fire Capital SE increased its holdings in Fractyl Health by 84.5% in the 1st quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after purchasing an additional 2,711,103 shares during the last quarter. Accredited Investors Inc. purchased a new stake in Fractyl Health in the first quarter valued at approximately $46,000. Virtu Financial LLC purchased a new stake in Fractyl Health in the fourth quarter valued at approximately $153,000. Susquehanna Portfolio Strategies LLC purchased a new stake in Fractyl Health in the fourth quarter valued at approximately $108,000. Finally, Quadrature Capital Ltd raised its position in Fractyl Health by 2,047.1% in the fourth quarter. Quadrature Capital Ltd now owns 290,714 shares of the company’s stock valued at $640,000 after purchasing an additional 277,174 shares during the period.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.